
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis
November 2025 Updates to AASLD Practice Guidance</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Semaglutide Therapy for Metabolic Dysfunction-Associated Steatohepatitis</strong><br><em>November 2025 Updates to AASLD Practice Guidance</em></summary>
            <div>
                <ul><li>- <b>Journal:</b> Hepatology</li><li>- <b>Publication Date:</b> November 2025 (Publish Ahead of Print)</li><li>- <b>DOI:</b> 10.1097/HEP.0000000000001608</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What is the recommended VCTE LSM range for selecting MASH patients for semaglutide?</li><li>- What percentage of total weight loss does lean mass loss constitute with semaglutide therapy?</li><li>- What is the recommended daily protein intake to mitigate sarcopenia risk?</li><li>- What was the absolute risk reduction in the composite cardiovascular endpoint in the SELECT trial?</li><li>- What is the half-life of semaglutide?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>FDA Approval & Indication (Wegovy®)</strong></summary>
            <div>
                <ul><li>- <b>Drug:</b> Semaglutide (Wegovy® formulation).</li><li>- <b>Approval:</b> <u>Accelerated FDA approval</u> on <q><b>August 15, 2025</b></q>.</li><li>- <b>Indication:</b> Treatment of MASH with <u>moderate-to-advanced fibrosis</u> (consistent with stages F2-F3).</li></ul>
                
        <details>
            <summary><strong>Basis for Approval: ESSENCE Trial (Phase 3)</strong></summary>
            <div>
                <ul><li>- Based on interim results from the first 800 participants.</li><li>- Final approval is contingent on long-term outcomes, expected in <q><b>2028 or later</b></q>.</li></ul>
                
        <details>
            <summary><strong>Primary Histologic Endpoints (at 72 weeks)</strong></summary>
            <div>
                <ul><li>- <b>Dose:</b> <q><b>2.4 mg/week</b></q> subcutaneous injection.</li><li>- Both primary endpoints were achieved.</li></ul>
                
        <details>
            <summary><strong>MASH Resolution</strong></summary>
            <div>
                <ul><li>- <u>Resolution of MASH</u> without worsening of fibrosis.</li><li>- Achieved in <q><b>62.9%</b></q> of patients vs. 34.3% with placebo (p<0.001).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Fibrosis Improvement</strong></summary>
            <div>
                <ul><li>- <u>>1 stage reduction in liver fibrosis</u> without worsening of MASH.</li><li>- Achieved in <q><b>36.8%</b></q> of patients vs. 22.4% with placebo (p<0.001).</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Approved Indications for Semaglutide</strong></summary>
            <div>
                <ul><li>- <b>Chronic Weight Management (2021):</b> Adults with obesity or overweight with at least one weight-related comorbidity.</li><li>- <b>Pediatric Weight Management (2022):</b> Patients aged 12 years and older.</li><li>- <b>Cardiovascular Risk Reduction (2024):</b> Adults with established CV disease and either obesity or overweight.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Patient Selection: Whom to Treat</strong></summary>
            <div>
                <ul><li>- <u>Key candidates:</u> Patients with MASH and fibrosis stage <b>F2-F3</b>.</li><li>- <u>Methodology:</u> Identification should be based on <b>Non-Invasive Tests (NITs)</b> rather than liver biopsy, which is deemed impractical for most patients.</li></ul>
                
        <details>
            <summary><strong>Recommended NIT Cutoffs for Treatment Eligibility</strong></summary>
            <div>
                <ul><li>- These ranges are recommended to identify patients with F2-F3 fibrosis.</li></ul>
                
        <details>
            <summary><strong>VCTE (Vibration Controlled Transient Elastography)</strong></summary>
            <div>
                <ul><li>- Recommended LSM range: <q><b>8–15 kPa</b></q>.</li><li>- This range included approximately <q><b>50%</b></q> of the ESSENCE study population.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>MRE (Magnetic Resonance Elastography)</strong></summary>
            <div>
                <ul><li>- Recommended LSM range: <q><b>3.1–4.4 kPa</b></q>.</li><li>- MRE was not used in ESSENCE, but criteria are extrapolated from prior studies.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ELF™ (Enhanced Liver Fibrosis) Score</strong></summary>
            <div>
                <ul><li>- Recommended range: <q><b>9.2–10.5</b></q>.</li><li>- This range identified approximately <q><b>50%</b></q> of participants in ESSENCE with histological F2-3.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Individualized Decision Zone (Higher NIT values)</strong></summary>
            <div>
                <ul><li>- For patients with NIT values in these higher ranges, an individualized decision to treat is needed after excluding cirrhosis.</li></ul>
                
        <details>
            <summary><strong>NIT Ranges</strong></summary>
            <div>
                <ul><li>- <b>VCTE:</b> <q><b>15-20 kPa</b></q></li><li>- <b>MRE:</b> <q><b>4.4-5.0 kPa</b></q></li><li>- <b>ELF:</b> <q><b>10.5-11.3</b></q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Exclusion of Cirrhosis</strong></summary>
            <div>
                <ul><li>- Use a confirmatory NIT.</li><li>- Use cross-sectional imaging to exclude nodular liver contour or signs of portal hypertension.</li><li>- Check for platelet count < <q><b>150,000/mm3</b></q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Populations Not Recommended for MASH Indication</strong></summary>
            <div>
                <ul><li>- <b>MASH Cirrhosis:</b> Not approved for this indication.</li><li>- Defined by VCTE > <q><b>20 kPa</b></q>, MRE > <q><b>5.0 kPa</b></q>, or ELF > <q><b>11.3</b></q>.</li><li>- Note: Patients with <u>compensated cirrhosis</u> receiving semaglutide for another approved indication should be monitored carefully.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Role of FIB-4</strong></summary>
            <div>
                <ul><li>- A FIB-4 score < <q><b>1.3</b></q> effectively excludes advanced fibrosis (F3+).</li><li>- A FIB-4 score ≥ 1.3 has a weak positive predictive value.</li><li>- <u>Should not be used as a single rule-in or rule-out test</u>; AASLD recommends a sequential testing strategy.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Consideration of Alcohol Use</strong></summary>
            <div>
                <ul><li>- ESSENCE trial allowed mild alcohol use (up to <q><b>20 g/d in women / 30 g/d in men</b></q>).</li><li>- Alcohol consumption should be assessed with <b>AUDIT-C</b> and <b>PEth</b> testing.</li><li>- Decisions to treat patients with moderate alcohol consumption must be individualized.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Monitoring During Treatment</strong></summary>
            <div>
                <ul><li>- Monitoring parameters are similar to other Wegovy® indications.</li></ul>
                
        <details>
            <summary><strong>Hepatic Function Monitoring</strong></summary>
            <div>
                <ul><li>- In the ESSENCE trial, hepatic function was tested every 12 weeks.</li><li>- Result: <q><b>None</b></q> of the 538 participants stopped treatment due to elevated ALT or AST.</li><li>- <b>Recommendation:</b> Hepatic function panels should be performed <u>as clinically indicated</u>, not on a strict schedule.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Adverse Event Monitoring</strong></summary>
            <div>
                <ul><li>- Monitor for common GI adverse events (nausea, diarrhea, constipation, vomiting).</li><li>- Screen for active suicidal ideation; if present, do not initiate until stable and under care of a mental health professional.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Adverse Events & Safety Monitoring</strong></summary>
            <div>
                <ul><li>- Overall adverse event rate: <q><b>86.2%</b></q> with semaglutide vs. 79.7% with placebo.</li><li>- Discontinuation rates due to adverse events were similar: <q><b>2.6%</b></q> (semaglutide) vs. 3.3% (placebo).</li></ul>
                
        <details>
            <summary><strong>Gastrointestinal (GI) Disorders (Most Common)</strong></summary>
            <div>
                <ul><li>- Most GI side effects were mild/moderate and transient.</li></ul>
                
        <details>
            <summary><strong>Incidence vs. Placebo</strong></summary>
            <div>
                <ul><li>- <b>Nausea:</b> <q><b>36.2%</b></q> vs. 13.2%</li><li>- <b>Diarrhea:</b> <q><b>26.9%</b></q> vs. 12.2%</li><li>- <b>Constipation:</b> <q><b>22.2%</b></q> vs. 8.4%</li><li>- <b>Vomiting:</b> <q><b>18.6%</b></q> vs. 5.6%</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Management Strategies</strong></summary>
            <div>
                <ul><li>- <b>Patient Education:</b> Stop eating when feeling full to avoid nausea/bloating.</li><li>- <b>Dose Titration:</b> Gradual increase in dose.</li><li>- <b>Dietary:</b> Smaller, lower-fat meals, adequate hydration, dietary fiber.</li><li>- <b>Supportive Meds:</b> Antiemetics, prokinetics, or antidiarrheals if needed.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Key Safety Considerations (See Table 3)</strong></summary>
            <div>
                <ul><li>- A summary of rare but serious risks requiring clinical awareness.</li></ul>
                
        <details>
            <summary><strong>Acute Kidney Injury (AKI)</strong></summary>
            <div>
                <ul><li>- <b>Cause:</b> Volume depletion from GI side effects.</li><li>- <b>Action:</b> Ensure hydration, monitor serum creatinine/eGFR, especially during dose titration.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Acute Pancreatitis</strong></summary>
            <div>
                <ul><li>- <b>Action:</b> Discontinue promptly if suspected. Avoid re-initiation after a confirmed episode.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Gallbladder Disease</strong></summary>
            <div>
                <ul><li>- <b>Risk:</b> Significantly increased risk. A meta-analysis showed a <q><b>37%</b></q> increased risk of gallbladder/biliary diseases.</li><li>- <b>Incidence:</b> Cholelithiasis (<q><b>1.6%</b></q> vs 0.7%), Cholecystitis (<q><b>0.6%</b></q> vs 0.2%).</li><li>- <b>Action:</b> Educate patients on symptoms; use caution in those with a history of gallbladder disease.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Thyroid C-cell Tumors</strong></summary>
            <div>
                <ul><li>- <b>Warning:</b> <u>Black box warning</u> for risk of medullary thyroid carcinoma (MTC).</li><li>- <b>Contraindication:</b> Personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Hypoglycemia</strong></summary>
            <div>
                <ul><li>- <b>Risk:</b> Low with monotherapy, but increases when used with <u>insulin or sulfonylureas</u>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Heart Rate Increase</strong></summary>
            <div>
                <ul><li>- <b>Mechanism:</b> Direct chronotropic effect on the sinoatrial node.</li><li>- <b>Action:</b> Instruct patients to report palpitations or a racing heartbeat at rest.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Gastroparesis</strong></summary>
            <div>
                <ul><li>- <b>Risk:</b> Can precipitate gastroparesis in rare cases.</li><li>- <b>Contraindication:</b> Use in severe gastroparesis is contraindicated.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Diabetic Retinopathy</strong></summary>
            <div>
                <ul><li>- <b>Risk:</b> May increase complications, especially during rapid glycemic improvement.</li><li>- <b>SUSTAIN-6 Trial:</b> Complications occurred in <q><b>3.0%</b></q> of semaglutide patients vs. 1.8% in placebo.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Lean Mass Loss / Sarcopenia</strong></summary>
            <div>
                <ul><li>- Lean mass loss constitutes about <q><b>39%</b></q> of total weight reduction.</li><li>- Appendicular skeletal muscle volume declines by <q><b>9–10%</b></q> over two years.</li></ul>
                
        <details>
            <summary><strong>Mitigation Strategies</strong></summary>
            <div>
                <ul><li>- <b>Protein Intake:</b> Ensure adequate intake of <q><b>1.2–1.5 g/kg/day</b></q>.</li><li>- <b>Exercise:</b> Encourage resistance training.</li><li>- <b>Monitoring:</b> Closely monitor older or sarcopenic adults.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Assessing Response to Treatment</strong></summary>
            <div>
                <ul><li>- No single NIT reliably predicts histologic response at the individual level.</li><li>- The following are suggested markers of a beneficial response at <u>72 weeks</u>.</li></ul>
                
        <details>
            <summary><strong>Criteria for Beneficial Response</strong></summary>
            <div>
                <ul><li>- These thresholds suggest a significant improvement and likely reflect a beneficial response.</li></ul>
                
        <details>
            <summary><strong>Fibrosis Improvement Markers</strong></summary>
            <div>
                <ul><li>- <b>VCTE LSM:</b> Decrease ≥ <q><b>30%</b></q></li><li>- <b>MRE LSM:</b> Decrease ≥ <q><b>20%</b></q></li><li>- <b>ELF Score:</b> Decrease ≥ <q><b>0.5</b></q></li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>MASH Resolution Markers</strong></summary>
            <div>
                <ul><li>- <b>ALT:</b> Decrease > <q><b>17 U/L</b></q> or ≥ <q><b>20%</b></q></li><li>- <b>CAP:</b> Decrease > <q><b>30%</b></q></li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Assessing Futility (Non-Response)</strong></summary>
            <div>
                <ul><li>- In ESSENCE, <q><b>37.1%</b></q> of participants did not resolve MASH, and <q><b>63.2%</b></q> did not have fibrosis reduction by Week 72.</li><li>- <b>Suspect non-response if:</b></li><li>- - Lack of decline in ALT or liver stiffness.</li><li>- - Worsening of NIT parameters.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Concomitant Therapy</strong></summary>
            <div>
                <ul><li>- <b>Lifestyle Modification:</b> Remains the <u>cornerstone</u> of MASLD management, including nutrition, exercise, and behavior modification.</li></ul>
                
        <details>
            <summary><strong>Combination with Resmetirom</strong></summary>
            <div>
                <ul><li>- The combination of semaglutide 2.4 mg/week and resmetirom has <u>not been studied</u>.</li><li>- In the MAESTRO-NASH trial, <q><b>14%</b></q> of participants were on a GLP-1 RA and showed similar rates of MASH resolution and fibrosis improvement.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Other Therapies</strong></summary>
            <div>
                <ul><li>- <b>Vitamin E (≥800 IU/day) & Pioglitazone:</b> Patients were excluded from ESSENCE if these were not at a stable dose for 90 days prior to baseline.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Semaglutide & Cardiometabolic Risk Factors</strong></summary>
            <div>
                <ul><li>- Cardiovascular disease is the <u>most common cause of death</u> in patients with MASH.</li></ul>
                
        <details>
            <summary><strong>Obesity (STEP Trials)</strong></summary>
            <div>
                <ul><li>- MASLD guidance recommends <q><b>>10%</b></q> weight loss to reverse fibrosis.</li><li>- <b>STEP 1:</b> Average weight loss of <q><b>14.9%</b></q>.</li><li>- <b>STEP 2 (with T2DM):</b> Average weight loss of <q><b>9.6%</b></q>.</li><li>- <b>STEP 3 (with behavioral therapy):</b> Average weight loss of <q><b>16%</b></q>.</li><li>- <u>Discontinuation leads to weight regain</u> and reversal of cardiometabolic benefits.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Cardiovascular Risk Reduction</strong></summary>
            <div>
                <ul><li>- <b>SUSTAIN-6 Trial (Ozempic® in T2DM):</b> Showed a <q><b>2.3%</b></q> absolute risk reduction in major adverse cardiovascular events (MACE).</li><li>- <b>SELECT Trial (Wegovy® in Obesity without Diabetes):</b> Demonstrated a <q><b>1.5%</b></q> absolute risk reduction in MACE over ~40 months.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Chronic Kidney Disease (CKD) (FLOW Trial)</strong></summary>
            <div>
                <ul><li>- For patients with T2DM and CKD, semaglutide 1.0 mg weekly showed a <q><b>24%</b></q> relative risk reduction in a composite of kidney failure, CV death, and other renal events.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Endocrinologic Considerations & Mechanism of Action</strong></summary>
            <div>
                <ul><li>- Semaglutide is a GLP-1 Receptor Agonist with <q><b>94%</b></q> sequence homology to human GLP-1.</li><li>- It has a long half-life of approximately <q><b>5-7 days</b></q>, allowing for once-weekly dosing.</li></ul>
                
        <details>
            <summary><strong>Hepatic Effects (Indirect)</strong></summary>
            <div>
                <ul><li>- GLP-1 receptor expression is <u>negligible on hepatocytes</u> and other resident liver cells.</li><li>- Hepatoprotective benefits are mediated <b>indirectly</b> via:</li><li>- - Sustained weight reduction.</li><li>- - Improved glycemic and lipid profiles.</li><li>- - Reduction of hepatic and systemic inflammation.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Systemic Effects</strong></summary>
            <div>
                <ul><li>- <b>Pancreas:</b> Stimulates glucose-dependent insulin release and suppresses glucagon release.</li><li>- <b>Central Nervous System:</b> Mediates appetite suppression by activating GLP-1Rs in the hypothalamus and hindbrain.</li><li>- <b>Lipid Metabolism:</b> Inhibits chylomicron synthesis, decreases de novo lipogenesis, and reduces VLDL production.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Summary of Recommendations</strong></summary>
            <div>
                <ul><li>- This section provides a condensed overview of the key guidance points.</li></ul>
                
        <details>
            <summary><strong>FDA Indication</strong></summary>
            <div>
                <ul><li>- Semaglutide (Wegovy®) is approved for <b>MASH with F2-F3 fibrosis</b> based on ESSENCE trial interim results showing significant MASH resolution and fibrosis improvement.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Patient Selection</strong></summary>
            <div>
                <ul><li>- Use NITs to identify candidates: <b>VCTE (8–15 kPa)</b>, <b>MRE (3.1–4.4 kPa)</b>, or <b>ELF (9.2–10.5)</b>.</li><li>- Avoid routine liver biopsy.</li><li>- Not approved for MASH cirrhosis.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Monitoring & Safety</strong></summary>
            <div>
                <ul><li>- Favorable hepatic safety profile; monitor liver enzymes only as clinically indicated.</li><li>- Manage common GI side effects with patient education and dose titration.</li><li>- Be aware of rare but serious risks like pancreatitis, gallbladder disease, and lean mass loss.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Treatment Response</strong></summary>
            <div>
                <ul><li>- Lifestyle modification is essential.</li><li>- Response can be suggested by significant reductions in NITs (e.g., VCTE LSM >30%, MRE LSM >20%, ALT >20%).</li><li>- Suspect non-response if NITs worsen.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
